Right now, most Americans are still awaiting their first dose of the COVID-19 vaccine.
And as more vaccines emerge and more research is done, recommendations regarding which vaccines are best for certain populations may emerge.
The FDA released its own analysis ahead of the meeting that showed the vaccine was highly effective in preventing severe Covid-19, including newer variants.
That would be on top of already expected increases for the state's vaccine supply: Reed said 145,000 doses are expected next week, and 156,000 doses are expected the week after that, not including estimates for the Johnson & Johnson vaccine.
"Having additional vaccines from different manufacturers can help to get more people vaccinated sooner", she said, adding that the department has concluded "that the benefits outweigh the risks". After adding in moderate cases, the total effectiveness dropped to about 66 percent.
This makes it slightly less protective than the Pfizer and Moderna's two-shot regimens, which both have an efficacy of around 95 percent against all forms of Covid-19 from the classic coronavirus strain. This is White House coronavirus response coordinator Jeffrey Zients.
If the panel votes that the vaccine's benefits outweigh its risks, as expected, the agency could grant emergency clearance within days, providing a badly needed boost to USA vaccine supplies.
US health advisers endorsed a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, putting the nation on the cusp of adding an easier-to-use option to fight the pandemic.
If the J&J vaccine is authorised, U.S. officials expect to have only a few million doses to divide between states in initial shipments. So while protection from moderate cases may be less robust, a newly reported 100% protection against deaths and hospitalizations is "huge", said Dr. Darien Sutton, an emergency medicine physician and ABC News contributor. "When it's your turn, you should take whichever one is offered". For example, it's a logical choice for homeless shelters where people may have moved on before their second dose of the Pfizer or Moderna vaccine.
Given the current rates of vaccine development and production, experts estimate that most adults who want to be vaccinated should be able to do so by the summer, said Marc Siegel, an associate professor of medicine in the Division of Infectious Diseases at George Washington University.
J&J's vaccine protects against the worst effects of COVID-19 after one shot, and it can be stored up to three months at refrigerator temperatures, making it easier to handle than the previous vaccines, which must be frozen.
"I think I was a little bit surprised that Health Canada did approve it for folks who are 65 and older".
But when it comes to delivering the two new vaccines, it seems Canada may have already hit a snag. AstraZeneca's vaccine, for instance, is cleared for use in Britain and Europe after data suggested it was about 70 percent effective.
Trudeau spoke on Friday hours after Health Canada announced it had approved a COVID-19 vaccine from AstraZeneca.
In the United States, health officials say it's critical for the government to send a clear message.
"Right now, it's not vaccine against vaccine, it's vaccine against virus", said Dr Nirav Shah, director of the Maine Center for Disease Control and Prevention.